A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study1-Reference-Cited by-同舟云学术

A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study1

Published:2006-04-01 Issue:2 Volume:8 Page:189-193
ISSN:1523-5866
Container-title:Neuro-Oncology
language:en
Short-container-title:

Author:

Prados Michael D.,Lamborn Kathleen,Yung W.K.A.,Jaeckle Kurt,Robins H. Ian,Mehta Minesh,Fine Howard A.,Wen Patrick Y.,Cloughesy Timothy,Chang Susan,Nicholas M. Kelly,Schiff David,Greenberg Harry,Junck Larry,Fink Karen,Hess Ken,Kuhn John

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Neurology (clinical),Oncology

Link

http://academic.oup.com/neuro-oncology/article-pdf/8/2/189/13066320/NO82_12_Prados.pdf

Reference12 articles.

1. Batchelor, T.T., Gilbert, M.R., Supko, J.G., Carson, K.A., Nabors, L.B., Grossman, S.A., Lesser, G.J., Mikkelsen, T., and Phuphanich, S. (2004) Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: Final report of NABTT 97-11. Neuro-Oncology6, 21-27.

2. Buckner, J.C., Reid, J.M., Wright, K., Kaufmann, S.H., Erlichman, C., Ames, M., Cha, S., O'Fallon, J.R., Schaaf, L.J., and Miller, L.L. (2003) Irinotecan in the treatment of glioma patients: current and future studies of the North Central Cancer Treatment Group. Cancer97 (suppl.), 2352-2358.

3. Chamberlain, M.C. (2002) Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J. Neurooncol.56, 183-188.

4. Cloughesy, T.F., Filka, E., Kuhn, J., Nelson, G., Kabbinavar, F., Friedman, H., Miller, L.L., and Elfring, G.L. (2003) Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer97 (suppl.), 2381-2386.

5. Friedman, H.S., Petros, W.P., Friedman, A.H., Schaaf, L.J., Kerby, T., Lawyer, J., Parry, M., Houghton, P.J., Lovell, S., Rasheed, K., Cloughesy, T., Stewart, E.S., Colvin, O.M., Provenzale, J.M., McLendon, R.E., Bigner, D.D., Cokgor, I., Haglund, M., Rich, J., Ashley, D., Malczyn, J., Elfring, G.L., and Miller, L.L (1999) Irinotecan therapy in adults with recurrent or progressive malignant glioma. J. Clin. Oncol.17, 1516-1525.

Cited by 185 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Local Delivery of Irinotecan to Recurrent GBM Patients at Reoperation Offers a Safe Route of Administration;Cancers;2024-08-29

2. Nanotechnology Driven Lipid and Metalloid Based Formulations Targeting Blood–Brain Barrier (3B) for Brain Tumor;Indian Journal of Microbiology;2024-06-21

3. Mechanisms of telomere maintenance and associated therapeutic vulnerabilities in malignant gliomas;Neuro-Oncology;2024-01-29

4. Targeting brain tumors with innovative nanocarriers: bridging the gap through the blood-brain barrier;Oncology Research;2024

5. Bevacizumab Alone Versus Bevacizumab Plus Irinotecan in Patients With Recurrent Glioblastoma: A Nationwide Population-Based Study;Journal of Korean Medical Science;2024